IDXX
ACCE-researchedIDEXX Laboratories Inc. Common Stock
Healthcare · Diagnostics & Research · NASDAQ · United States
$511.65+1.02%
Market cap $40.3BNext earnings 2026-11-02Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$511.65+0.0%
confidence-weighted across 4 of 6 models
Now $511.65
$511.65
$200.81$349.86
Avoid
Price vs fair value
94.4% above
-48.6% to fair value
ACCE score
53
out of 100
Analysts
46% buy
13 covering
P/E
36.0x
forward 30.9x
1-year return
-21.9%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOROverview
⚠ Investor warnings · 3 flags
- highExtreme valuation multiplesP/E 41.5x, EV/EBITDA 29.2x, P/S 9.6x leave minimal margin of safety; any growth disappointment risks sharp de-rating.
- moderateMomentum score very lowACCE Momentum score is 32/100, suggesting weak near-term price action despite strong fundamentals and recent score recovery.
- moderateValue score near zeroValue score of 25/100 confirms stock is priced for perfection; limited valuation buffer if earnings growth decelerates from current 17.2%.
Reports in 42 days, last quarter beat by 0.1%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
-20.6% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Mixed46% buy · 13 covering analysts
● Strong buy 3● Buy 3● Hold 6● Sell 1● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 33% of peers
low 0.0x36.0xhigh 106.5x
ROEbetter than 100% of peers
low -13%74%high 74%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 0.9%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| WAT | Waters Corporation Common Stock | $41.4B | 106.5 | 1.9% | 0.73 | 0.0% | - | Compare |
| IQV | IQVIA Holdings Inc. Common Stock | $43.9B | 33.1 | 22.8% | 2.42 | 0.0% | - | Compare |
| A | Agilent Technologies Inc. Common Stock | $44.1B | 30.9 | 21.0% | 0.50 | 0.7% | - | Compare |
| ILMN | Illumina Inc. Common Stock | $36.2B | 44.6 | 32.3% | 0.73 | 0.0% | - | Compare |
| LONN.SW | Lonza Group | $46.2B | 35.2 | 12.9% | 0.46 | 0.9% | - | Compare |
| NTRA | Natera Inc. Common Stock | $53.2B | - | -12.5% | 0.05 | 0.0% | - | Compare |
Sector report card
Where IDXX ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 42 days, last quarter beat by 0.1%.
Press releases mentioning this company
- Business Wire•Sep 17, 2026IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- Business Wire•Sep 16, 2026IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Business Wire•Aug 31, 2026IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
3 more press releases · full archive on Investor+.INVESTOR
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
+1.4%
1 month
-9.0%
3 months
-9.0%
6 months
-11.4%
YTD
-24.4%
1 year
-21.9%
SEC filings
40 filings
September 2026
Sep 9
Form 4Insider transactionPeriod 2026-09-04
August 2026
Aug 24
Form 4Insider transactionPeriod 2026-08-20
Aug 4
10-QQuarterly reportPeriod 2026-06-30
37 more filings + AI summaries on Investor+.INVESTOR